Unclaimed Shares of Alkem Laboratories Ltd.

Alkem Laboratories Ltd is one of India’s leading pharmaceutical companies, known for its extensive portfolio of generic medicines, active pharmaceutical ingredients (APIs), and nutraceuticals. Established in 1973 and headquartered in Mumbai, Alkem has emerged as a trusted name in the healthcare industry, providing high-quality and affordable medicines across diverse therapeutic areas such as cardiology, gastroenterology, neurology, anti-infectives, and pain management.

Alkem boasts a strong domestic presence and is consistently ranked among the top pharmaceutical companies in India in terms of sales. The company also has a significant international footprint, with a presence in over 50 countries, including key markets like the United States, Australia, Europe, and Southeast Asia. Its U.S.-based subsidiary, Ascend Laboratories, is a critical driver of its global growth, contributing substantially to its revenues.

Research and development (R&D) is a cornerstone of Alkems success, with dedicated facilities focusing on innovation and the development of complex generics, biosimilars, and specialty drugs. The company has over 800 products in its portfolio and continues to invest heavily in R&D to stay competitive in the evolving pharmaceutical landscape.

Alkem operates 21 manufacturing facilities, with several approved by global regulatory bodies like the U.S. FDA and the European Medicines Agency. These facilities ensure adherence to stringent quality standards.

Alkem Laboratories commitment to improving healthcare outcomes, coupled with its innovation-driven approach, has made it a trusted partner in the global pharmaceutical sector, serving millions of patients worldwide.

Company Details

• Registered Name: Alkem Laboratories Ltd.
• CIN Number: L00305MH1973PLC174201
• ISIN Number: INE540L01014

Dividend’s History of Alkem Laboratories Ltd.

Ex-Date	Dividend Amount	Dividend Type	Record Date
09 Aug 2024	5.00	FINAL	10 Aug 2024
16 Feb 2024	35.00	INTERIM	17 Feb 2024
10 Aug 2023	10.00	FINAL	10 Aug 2023
17 Feb 2023	25.00	SPECIAL	18 Feb 2023
17 Feb 2023	15.00	INTERIM	18 Feb 2023
08 Aug 2022	4.00	FINAL	10 Aug 2022
10 Feb 2022	30.00	INTERIM	12 Feb 2022
09 Aug 2021	5.00	FINAL	10 Aug 2021
11 Feb 2021	25.00	INTERIM	13 Feb 2022
10 Aug 2020	3.00	FINAL	11 Aug 2020
13 Feb 2020	22.00	INTERIM	15 Feb 2020
15 Feb 2019	8.00	INTERIM	18 Feb 2019
23 Aug 2018	7.00	FINAL	24 Aug 2018
16 Feb 2018	6.00	INTERIM	20 Feb 2018
31 Aug 2017	9.00	FINAL	01 Sep 2017
23 Nov 2016	6.00	INTERIM	24 Nov 2016
18 Mar 2016	9.70	INTERIM	21 Mar 2016

Bonus

NA

The company has historically focused on reducing debt and reinvesting profits into its operations and growth initiatives.

Split

NA

Mergers / Amalgamation

Alkem Laboratories Ltd has primarily grown through organic expansion and strategic investments rather than high-profile mergers or amalgamations. However, the company has engaged in select acquisitions and partnerships to strengthen its market position and global presence. Heres an overview of Alkem key mergers and acquisitions:

1. Ascend Laboratories (2008)
• Alkem established its wholly-owned subsidiary, Ascend Laboratories, in the United States. This was a strategic move to enter the lucrative U.S. generic drug market. Through Ascend, Alkem markets and distributes its products, which form a significant part of its international revenue.
2. Enzene Biosciences (2014)
• Alkem acquired Enzene Biosciences, a biotechnology company focused on biosimilars, biologics, and novel drug delivery platforms. This acquisition marked Alkems entry into the biopharmaceutical segment and reinforced its R&D capabilities.
3. Pharmaforce, Inc. (2019)
• Alkem acquired Pharmaforce, Inc., a U.S.-based contract development and manufacturing organization (CDMO). This acquisition was aimed at bolstering its injectables business and expanding its capabilities in the development of complex formulations for the U.S. market.
4. Cachet Pharmaceuticals (2010s)
• Alkem integrated Cachet Pharmaceuticals, a domestic subsidiary, to strengthen its position in Indias prescription drug market. Cachet specializes in high-quality pharmaceutical formulations.
5. Small Acquisitions for Market Expansion
• Over the years, Alkem has made smaller acquisitions in international markets to enhance its geographic footprint and product portfolio, particularly in Southeast Asia, Australia, and Europe.

Physical Shares of Alkem Laboratories Ltd.

Physical shares of Alkem Laboratories Ltd. are no longer eligible for trading on stock exchanges as per SEBI regulations implemented on April 1, 2019. Investors holding such shares must dematerialize them to trade or transfer ownership. Dematerialization involves converting physical share certificates into an electronic format through a Demat account held with a Depository Participant (DP).

Unclaimed Shares and Dividends of Alkem Laboratories Ltd.

Alkem Laboratories Ltd., in accordance with the Investor Education and Protection Fund (IEPF) regulations, has been transferring equity shares to the IEPF if dividends remain unclaimed for seven consecutive years. As per the rules under the Companies Act, 2013, shares of individuals who have not claimed their dividends for seven years are moved to the IEPF demat account.

For instance, unclaimed dividends and shares for financial years 2014-15 and beyond are being transferred, with a specific cutoff date. If the dividends have not been claimed by shareholders, their respective shares will be transferred to IEPF, and the original share certificates become void and non-negotiable. Affected shareholders are notified, and are given the chance to claim unclaimed dividends before the transfer happens.

FAQ about unclaimed shares of Alkem Laboratories Ltd.

Company Details

+91 9156701900

+91 9970651900

sales@clearclaim.in

Office No C-201, 2nd Floor, Vantage Tower, Bramha Corp, Opposite to Bavdhan Police Chowky, NDA Pashan Road, Bavdhan, Pune – 411021